Given that the importance of real-world outcomes and results are more acknowledged than ever before, we investigated the association between PIK3CA mutations and the time of disease recurrence in relation to adjuvant endocrine treatment in HR+/HER2− negative early and locally advanced breast cancer patients using data from everyday clinical practice in Croatia. Here, ERBB2 is linked to breast carcinoma.